-
Efficacy data also demonstrates 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant, the company said in a statement while announcing its phase 3 data analysis.
-
The Union Health Ministry on Thursday projected that it will be able to supply 27,99,290 doses to Telangana in July.
-
India has already asked the EU member countries to individually consider allowing Indians who have taken Covishield and Covaxin vaccines and want to travel to Europe.
-
This assertion came from Bharath Biotech, after Brazil indicated suspension of its contract with the Hyderabad-based vaccine maker after allegations of irregularities in the deal surfaced.
-
Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus.
-
The Covaxin contract to Brazil landed in controversy after the South American countrys Attorney General reportedly launched a probe into the deal.
-
Moderna's vaccine will be the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik
-
While the new Covid vaccine policy came into effect across the country, TS perhaps remains the only State that has adopted a measured, practical, and logical approach of vaccinating individuals who need them the most
-
Bharat Biotech's 'pre-submission' meeting with the World Health Organization (WHO) will take on Wednesday for the approval for Covaxin.
-
It is reprehensible to invoke religious fears to spread falsehood against vaccines
-
"New born calf serum is used in the manufacturing of viral vaccines. It is used for the growth of cells, but neither used in growth of SARS CoV2 virus nor in the final formulation," the company said in a statement.
-
Innovators with specialised expertise in product development, and large-scale manufacturing, should be allowed to maintain a differential pricing strategy for governments and private hospitals, says the Covaxin maker
-
This will be followed by the clinical trial of children in the age-group of 2-6 years.
-
Hyderabad firm stated that the data from efficacy and safety follow-up of Covaxin’s phase III trial is being analysed and compiled, and it will soon make the data from the final analysis public
-
With herd immunity and a significant percentage of the US population vaccinated, the pandemic is reducing, and keeping this in view, the USFDA communicated that no new emergency use authorization would be approved for new Covid-19 vaccines
-
The FDA recommended Ocugen to "pursue a Biologics Licence Application (BLA) submission instead of an EUA application" and "requested additional information and data".
-
These 44 crore doses of COVID-19 vaccines will be delivered by their makers between August and December 2021, the Union Health Ministry said.
-
The Finance Minister says Union govt must permit States to procure vaccines from foreign countries
-
Anvisa also approved a proposal to import Russia’s Sputnik V vaccine.
-
The Companies manufacturing COVID-19 vaccination in India have given only "Emergency Use Authorization for vaccinating people of 18 years age and above